Carmen J. Allegra

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• A framework to evaluate surrogate endpoints at the trial level: Analysis in colorectal cancer

  JNCI Journal of the National Cancer Institute · 2026-03-19

• Changing standard of care during a randomized trial: examples, considerations and guidelines

  JNCI Journal of the National Cancer Institute · 2026-01-18

• Phase 2 trial of CBX-12 for metastatic chemotherapy-refractory microsatellite stable colorectal cancer (ETCTN 10707).

  Journal of Clinical Oncology · 2026-01-10

• A novel framework to grade the quality of surrogate endpoints at the trial level: An analysis of surrogate endpoints used in colorectal cancer trials.

  Journal of Clinical Oncology · 2026-01-10

• Abstract B139: A panel of patient-derived organoid models from rare cancers for high-throughput preclinical pharmacology studies

  Molecular Cancer Therapeutics · 2025-10-22

• Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer

  Journal of Clinical Oncology · 2025-10-02

• NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

  Cancer Chemotherapy and Pharmacology · 2025-08-09

• p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy

  Nature Cancer · 2025-06-27 · 11 citations

• Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

  JCO Precision Oncology · 2025-05-01

• Abstract 1674: Combinatorial screen with standard of care and selected anticancer agents identifies multiple combinations with activity against a panel of patient-derived colorectal organoids

  Cancer Research · 2025-04-21 · 1 citations

• Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group

  JCO Precision Oncology · 2025-03-01 · 3 citations

• Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752.

  Journal of Clinical Oncology · 2025-01-27 · 4 citations

• Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

  JCO Precision Oncology · 2024-12-01 · 13 citations

• A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR

  Neoplasia · 2024-11-14 · 7 citations

• Phase III Evaluation of Treatment Combinations in Three-Arm Trials

  Journal of Clinical Oncology · 2024-10-28 · 3 citations